Please join Arnold & Porter for Part I of our in-person series designed for legal and business leaders at biotechnology companies focused on optimizing their licensing and partnering.

This program will take the form of a presentation and boardroom-style discussion focused on the strategic question of whether to license an asset. We will explore key considerations that inform licensing and partnering strategies, including:

• Out-licensing versus strategic alternatives
• Transaction structuring priorities, including diligence focus
• Intellectual property and exclusivity protections
• Regulatory pathways considerations
• Antitrust and Hart-Scott-Rodino Act compliance issues
• Tariff and pricing dynamics (including IRA and MFN considerations)

We look forward to a thoughtful and engaging discussion!